Sepsis Clinical Trial
Official title:
Effects of Dietary Fiber Enteral Nutrition on Bone Metabolism in Septic Patients
Verified date | November 2022 |
Source | Zhujiang Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Clinical and animal studies have found that sepsis can lead to a serious imbalance in the gut microecology, a reduction in probiotics, a reduction in short-chain fatty acid, a reduction in bone mass, and an increase in bone destruction, maintaining the stability of microecology can be one of the effective means of bone protection. But at present, the treatment of sepsis with early supplementation of probiotics is still controversial, and dietary fiber intake has significantly changed the composition of the microbiota, it may be a safe and effective method to prevent bone loss in sepsis. Further study on it will provide reliable theoretical basis and intervention target for early, safe and effective prevention of osteoporosis.
Status | Active, not recruiting |
Enrollment | 2 |
Est. completion date | December 31, 2024 |
Est. primary completion date | December 31, 2024 |
Accepts healthy volunteers | |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility | Inclusion Criteria: 1. The subjects voluntarily cooperated with the study and signed the informed consent form, and could be followed up 2. Age 18-70 3. It meets the diagnostic criteria of Sepsis 2016 Sepsis 3.0 guidelines 4. After treatment, the Hemodynamics is stable and the patient is ready to start enteral nutrition support 5. Those who need tube feeding for more than 14 days because of the need of illness and can not take food by mouth Exclusion Criteria: 1. People who have had osteoporosis in the past 2. Admission due to fracture 3. The shock was not corrected, and the patients were maintained with a large amount of vaso-active drugs (0.5 ug/kg/min of noradrenaline) , but could not be given enteral nutrition 4. Supplement with probiotics or prebiotics alone 5. Parturients 6. No written informed consent |
Country | Name | City | State |
---|---|---|---|
China | Zhujiang hospital | Guangzhou | Guangdong |
Lead Sponsor | Collaborator |
---|---|
Zhujiang Hospital |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The changes of bone metabolic markers ß-CTX | The venous blood was drawn daily before and after the enrollment (the first, third, seventh and fourteenth days) ,and ß- CTX for comparison | 28 day | |
Primary | The changes of bone metabolic markers PINP | 28 day | ||
Secondary | Changes in intestinal flora | Collect stool before and after the enrollment (the first, third, seventh and fourteenth days) ,observe the changes of intestinal flora in the two groups. Total bacterial DNA were extracted from samples using the QIAamp DNA stool Mini Kit from Qiagen according to the manufacture's protocol. | 28 day | |
Secondary | Changes in short-chain fatty acid of metabolites | Collect stool before and after the enrollment (the first, third, seventh and fourteenth days) ,observe the changes of metabolite short chain fatty acids in the two groups. Fresh feces were collected and frozen in liquid nitrogen timely.SCFAs was extracted and quantified using a Metrohm ion chromatograph(850 Professional Ic, Metrohm, Herisau, Switzerlan) system | 28 day | |
Secondary | Abdominal symptoms (abdominal distention) | To evaluate and compare the difference of abdominal symptoms (abdominal distension) between the two groups,It is divided into three levels according to the severity of abdominal distension, it can be divided into light, medium and severe (for example:Mild, soft abdomen, tolerable,Moderate: abdominal bulge, obvious discomfort,Severe: abdominal muscles are obviously tense/intolerable) | 28 day | |
Secondary | Abdominal symptoms ( diarrhea incidence) | To evaluate and compare the difference of abdominal symptoms (diarrhea incidence ) between the two groups,it can be divided into light, medium and severe (for example:Mild, 3-5 times/day, 250-500ml/day,Moderate:>5 times/day, 500-1000ml/day,Severity:>5 times/day,>1500ml/day) | 28 day | |
Secondary | The change of systemic inflammatory response index: the value of TNF-a in systemic inflammatory response | The changes of TNF-a were observed and compare before and after treatment, It can be tested in the laboratory of our hospital, the higher the value, the heavier the infection. | 28 day | |
Secondary | The change of systemic inflammatory response index: the value of IL-6 in systemic inflammatory response | The changes of IL-6 were observed and compare before and after treatment. It can be tested in the laboratory of our hospital, the higher the value, the heavier the infection | 28 day | |
Secondary | The change of systemic inflammatory response index: the value of Procalcitonin in systemic inflammatory response | The changes of procalcitonin were observed and compare before and after treatment, the higher the value, the heavier the infection | 28 day | |
Secondary | Length of ICU stay | The total hospitalization time were observed before and after treatment | 28 day | |
Secondary | Length of Apache II score | The total Apache II score were observed before and after treatment,The higher the score is, the more serious the disease is. | 28 day |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05095324 -
The Biomarker Prediction Model of Septic Risk in Infected Patients
|
||
Completed |
NCT02714595 -
Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens
|
Phase 3 | |
Completed |
NCT03644030 -
Phase Angle, Lean Body Mass Index and Tissue Edema and Immediate Outcome of Cardiac Surgery Patients
|
||
Completed |
NCT02867267 -
The Efficacy and Safety of Ta1 for Sepsis
|
Phase 3 | |
Completed |
NCT04804306 -
Sepsis Post Market Clinical Utility Simple Endpoint Study - HUMC
|
||
Recruiting |
NCT05578196 -
Fecal Microbial Transplantation in Critically Ill Patients With Severe Infections.
|
N/A | |
Terminated |
NCT04117568 -
The Role of Emergency Neutrophils and Glycans in Postoperative and Septic Patients
|
||
Completed |
NCT03550794 -
Thiamine as a Renal Protective Agent in Septic Shock
|
Phase 2 | |
Completed |
NCT04332861 -
Evaluation of Infection in Obstructing Urolithiasis
|
||
Completed |
NCT04227652 -
Control of Fever in Septic Patients
|
N/A | |
Enrolling by invitation |
NCT05052203 -
Researching the Effects of Sepsis on Quality Of Life, Vitality, Epigenome and Gene Expression During RecoverY From Sepsis
|
||
Terminated |
NCT03335124 -
The Effect of Vitamin C, Thiamine and Hydrocortisone on Clinical Course and Outcome in Patients With Severe Sepsis and Septic Shock
|
Phase 4 | |
Recruiting |
NCT04005001 -
Machine Learning Sepsis Alert Notification Using Clinical Data
|
Phase 2 | |
Completed |
NCT03258684 -
Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Sepsis and Septic Shock
|
N/A | |
Recruiting |
NCT05217836 -
Iron Metabolism Disorders in Patients With Sepsis or Septic Shock.
|
||
Completed |
NCT05018546 -
Safety and Efficacy of Different Irrigation System in Retrograde Intrarenal Surgery
|
N/A | |
Completed |
NCT03295825 -
Heparin Binding Protein in Early Sepsis Diagnosis
|
N/A | |
Not yet recruiting |
NCT06045130 -
PUFAs in Preterm Infants
|
||
Not yet recruiting |
NCT05361135 -
18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in S. Aureus Bacteraemia
|
N/A | |
Not yet recruiting |
NCT05443854 -
Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01)
|
Phase 3 |